Form 4: Aquestive Therapeutics Director Abigail Jenkins Granted 42,000 Stock Options

Aquestive Therapeutics, Inc. Director Abigail L. Jenkins was granted 42,000 non-qualified stock options with an exercise price of $3.41 per share, vesting fully on June 11, 2026.

Summary

• Abigail L. Jenkins, a Director of Aquestive Therapeutics, Inc. (AQST), acquired 42,000 non-qualified stock options.
• The transaction date for the option grant was June 11, 2025.
• Each option has an exercise price of $3.41, which is the same as the underlying common stock price at the time of grant.
• The options will vest 100% on June 11, 2026, contingent upon Ms. Jenkins' continuous service with the Issuer from the grant date.
• The expiration date for these options is June 11, 2035.
• Following this transaction, Ms. Jenkins beneficially owns 42,000 derivative securities (options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the option grant aligns the director's interests with shareholders, which is generally viewed favorably, though it is a routine compensation event.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of executive and director compensation, indicating routine corporate governance practices.

Negatives

• No specific negative aspects are disclosed in this routine insider transaction filing.

Risks

• No new specific risks are disclosed in this Form 4 filing; however, the value of the options is subject to the future market price of Aquestive Therapeutics, Inc. common stock.

Future Outlook

This filing primarily reports a past transaction and does not provide forward-looking statements regarding company performance or financial guidance, beyond the vesting schedule of the options.

Industry Context

The granting of stock options to directors is a common practice across various industries, including the pharmaceutical and biotechnology sectors, as a means of compensation and to align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of non-qualified stock options with a vesting schedule is a standard compensation mechanism for directors and executives in publicly traded companies, consistent with common industry practices.
• The exercise price being equal to the stock's market price on the grant date is typical for such grants, ensuring that the options only gain value if the stock price appreciates.

Related Party Transactions

• The grant of non-qualified stock options to Director Abigail L. Jenkins constitutes a transaction with a related party, which is a standard component of director compensation.

Stakeholder Impact

• Shareholders: The option grant aims to align the director's long-term interests with shareholder value creation, potentially leading to improved governance and performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The options will vest on June 11, 2026, provided Ms. Jenkins continues her service with Aquestive Therapeutics, Inc.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Vesting, Pharmaceuticals, Biotechnology